Get the Stockscreener App
0.5545
0.81%
0.00445
Passage Bio Inc stock is traded at $0.5545, with a volume of 11,481.
It is up +0.81% in the last 24 hours and down -10.14% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
See More
Previous Close:
$0.55
Open:
$0.543
24h Volume:
11,481
Relative Volume:
0.02
Market Cap:
$33.97M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-0.4739
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
-0.99%
1M Performance:
-10.14%
6M Performance:
-25.75%
1Y Performance:
-55.29%
1-Day Range:
$0.5423
$0.565
1-Week Range:
$0.5202
$0.5917
52-Week Range:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.5545 | 33.97M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.69 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.46 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.77 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.90 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.94 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Passage Bio (NASDAQ:PASG) versus SpringWorks Therapeutics (NASDAQ:SWTX) Head to Head Review - Defense World
Passage Bio will again trim workforce in latest cost-cutting move - The Business Journals
Passage Bio CFO sells shares worth $1,685 - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Passage Bio CFO sells shares worth $1,685 By Investing.com - Investing.com UK
2024 Q4 Job Market Report: Biopharma Job Postings Slowed as Layoffs Continued - BioSpace
Passage Bio shares transition to Nasdaq Capital Market - MSN
Passage Bio shares transition to Nasdaq Capital Market By Investing.com - Investing.com South Africa
TELA Bio Grants Inducement Stock Units to New Employees - MyChesCo
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics - MSN
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Orbimed advisors reduces stake in Passage Bio for $142,223 By Investing.com - Investing.com South Africa
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MSN
Orbimed advisors reduces stake in Passage Bio for $142,223 - Investing.com
Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's - BioSpace
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway - BioSpace
Geode Capital Management LLC Has $351,000 Position in Nutriband Inc. (NASDAQ:NTRB) - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Geode Capital Management LLC - Defense World
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Head-To-Head Comparison: Passage Bio (NASDAQ:PASG) vs. JATT Acquisition (NYSE:JATT) - Defense World
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):